Xebio Holdings Co. Ltd. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, was ¥17.52 per share, a decline of 65.8% from ¥51.22 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥790.8 million, a decrease of 65.8% from ¥2.31 billion in the prior-year period.
The normalized profit margin dropped to 1.5% from 4.5% in the year-earlier period.
Total revenue climbed 5.9% year over year to ¥54.36 billion from ¥51.33 billion, and total operating expenses increased 11.4% year over year to ¥53.39 billion from ¥47.91 billion.
Reported net income declined 66.7% year over year to ¥701.8 million, or ¥15.55 per share, from ¥2.11 billion, or ¥46.75 per share.
As of Feb. 12, US$1 was equivalent to ¥118.90.
